Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC

This article was originally published in The Pink Sheet Daily

Executive Summary

Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.
Advertisement

Related Content

Market For Sanofi And Regeneron’s Zaltrap Could Be Limited
Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?
Roche Upbeat On Recent Launches, Oncology And Actemra To Drive Growth Through Mid-Term
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings
Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings

Topics

Advertisement
UsernamePublicRestriction

Register

PS072164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel